The diagnostic challenges in SCLC are primarily manifested in two aspects: first, most patients are already in advanced stages at diagnosis, with traditional serological markers NSE and ProGRP having limited diagnostic performance; second, the high molecular heterogeneity of SCLC makes early diagnosis difficult to achieve with single biomarkers. Here, ENO2 is linked to small cell lung carcinoma.